Radiation therapy (RT) is central to the management of unresectable stage I to III NSCLC.
However, the impact of actionable genetic driver alterations (AGAs) on locoregional control (LRC) from RT remains uncertain.
A retrospective, multicenter real-world study was undertaken to determine if common AGAs impact LRC after RT.
